Evidence map›Paper›PMID 25687688›Full record

ReviewAmerican journal of clinical dermatology2015

Cutaneous leishmaniasis: recent developments in diagnosis and management.

Henry J C de Vries, Sophia H Reedijk, Henk D F H Schallig

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in American journal of clinical dermatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04500873 (Diagnostic Performance of a Recombinant Polymerase Amplification Test - Lateral Flow), which is not on this map. Cited by 178 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
178citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04500873 completednot on this mapstarted 2018, after this paper: background citation

Diagnostic Performance of a Recombinant Polymerase Amplification Test - Lateral Flow (RPA-LF) for Cutaneous Leishmaniasis in an Endemic Setting of Colombia

TypeobservationalSponsorCentro Internacional de Entrenamiento e Investigaciones MédicasRan2018 to 2019Enrolled128ConditionsCutaneous Leishmaniasis (Diagnosis)
3 · Its place in the literature

Who cites it

178 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Interventions for Old World cutaneous leishmaniasis.The Cochrane database of systematic reviews · 2017
    Pooled it
  7. Interventions for Old World cutaneous leishmaniasis.The Cochrane database of systematic reviews · 2017
    Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Review
  15. Observational
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

118 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Henry J C de VriesDepartment of Dermatology, Academic Medical Center (AMC), University of Amsterdam, P.O. Box 22700, 1100 DE, Amsterdam, The Netherlands, h.j.devries@amc.nl.
Sophia H Reedijk
Henk D F H Schallig

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This review focuses on recent developments in the diagnosis, treatment, management, and strategies for the prevention and control of cutaneous leishmaniasis (CL) caused by both Old and New World Leishmania species. CL is caused by the vector-borne protozoan parasite Leishmania and is transmitted via infected female sandflies. The disease is endemic in more than 98 countries and an estimated 350 million people are at risk. The overall prevalence is 12 million cases and the annual incidence is 2-2.5 million. The World Health Organization considers CL a severely neglected disease and a category 1 emerging and uncontrolled disease. The management of CL differs from region to region and is primarily based on local experience-based evidence. Most CL patients can be treated with topical treatments, but some Leishmania species can cause mucocutaneous involvement requiring a systemic therapeutic approach. Moreover, Leishmania species can vary in their sensitivity to available therapeutic options. This makes species determination critical for the choice of treatment and the clinical outcome of CL. Identification of the infecting parasite used to be laborious, but now the Leishmania species can be identified relatively easy with new DNA techniques that enable a more rational therapy choice. Current treatment guidelines for CL are based on poorly designed and reported trials. There is a lack of evidence for potentially beneficial treatments, a desperate need for large well-conducted studies, and standardization of future trials. Moreover, intensified research programs to improve vector control, diagnostics, and the therapeutic arsenal to contain further incidence and morbidity are needed.

Indexed as

AnimalsHumansIncidenceLeishmaniasis, CutaneousPrevalence

Identifiers

PMID25687688
PMCPMC4363483

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.